Physician profile
Paul Yu
NPI 1497763627
$1,077.06
in general payments reported to CMS, 2019-2025
21 companies · $44.08 in 2025
The $44.08 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $225 · 2021: $92.83 · 2022: $148 · 2023: $81.66 · 2024: $316 · 2025: $44.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $442.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $242.69 | 2019-2021 | |
| Abbvie INC. | $143.41 | 2021-2024 | Vraylar |
| Lilly USA, LLC | $143.37 | 2023-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals Lp | $119.41 | 2024 | Airsupra |
| Novo Nordisk INC | $79.55 | 2019-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.90 | 2020-2025 | Jardiance |
| Medtronic, INC. | $27.74 | 2022 | |
| Merck Sharp & Dohme LLC | $27.10 | 2020 | |
| Validus Pharmaceuticals LLC | $22.90 | 2025 | Raldesy |
| Amarin Pharma, INC. | $21.41 | 2020 | |
| Sanofi Pasteur INC. | $20.63 | 2023 | |
| Arbor Pharmaceuticals, INC. | $20.01 | 2019 | |
| Astellas Pharma US INC | $19.92 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $19.15 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $19.13 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $17.86 | 2022 | |
| Abbott Laboratories | $17.58 | 2021 | |
| Glaxosmithkline, LLC. | $17.49 | 2022 | |
| Genentech USA, INC. | $16.03 | 2019 | |
| Allergan, INC. | $15.39 | 2020 | |
| Scilex Pharmaceuticals INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.